#1 Clinical Trials Search in Europe

Tebipenem Pivoxil Hydrobromide

Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) is an innovative oral antibiotic being studied in various clinical trials. This article summarizes key findings from these trials, exploring its potential use in treating infections, its effects on the body, and how it interacts with other medications. The research aims to establish the safety, effectiveness, and optimal dosing of this new drug across different patient groups.

Table of Contents

What is Tebipenem Pivoxil Hydrobromide?

Tebipenem Pivoxil Hydrobromide, also known as TBPM-PI-HBr or SPR994, is a new antibiotic medication being developed for treating various infections[1]. It belongs to a class of antibiotics called carbapenems, which are known for their broad-spectrum activity against many types of bacteria[1]. What makes Tebipenem unique is that it can be taken orally, whereas most other carbapenem antibiotics need to be given intravenously (through a vein)[1].

How Does Tebipenem Work?

Tebipenem works by interfering with the cell wall formation of bacteria. This action prevents bacteria from growing and multiplying, ultimately leading to their death. As a broad-spectrum antibiotic, it can target a wide range of bacteria, including those that may be resistant to other types of antibiotics[1].

What Conditions Does Tebipenem Treat?

Based on the clinical trials information, Tebipenem is being studied for the treatment of several conditions:

  • Complicated Urinary Tract Infections (cUTIs): These are urinary tract infections that are more difficult to treat, often due to underlying conditions or resistant bacteria[1].
  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI): These are serious skin infections that often require antibiotic treatment[1].
  • Diabetic Foot Infections: These are infections that occur in the feet of people with diabetes, which can be particularly challenging to treat[1].

How is Tebipenem Administered?

Tebipenem Pivoxil Hydrobromide is administered orally in tablet form. In the clinical trials, doses ranged from 300 mg to 600 mg, taken every 8 hours[1]. The exact dosage and duration of treatment would be determined by a healthcare provider based on the specific infection being treated and other individual factors.

Clinical Studies on Tebipenem

Several clinical trials are being conducted to evaluate Tebipenem’s effectiveness and safety:

  • Tissue Penetration Study: This study is looking at how well Tebipenem penetrates into the soft tissues of patients with diabetic foot infections compared to healthy volunteers[1].
  • Renal Impairment Study: This study is evaluating how Tebipenem behaves in the body of people with various degrees of kidney function, including those on dialysis[2].
  • Bioequivalence Study: This study is comparing different tablet formulations of Tebipenem to ensure they deliver the same amount of medication to the body[3].
  • QT Interval Study: This study is assessing whether Tebipenem affects heart rhythm, specifically the QT interval on an electrocardiogram (ECG)[4].
  • Drug Interaction Studies: These studies are looking at how Tebipenem interacts with other medications, such as antacids and omeprazole (a medication used to reduce stomach acid)[5].

Safety Profile and Side Effects

As Tebipenem is still in clinical trials, its full safety profile is not yet established. However, the studies are closely monitoring for any adverse events (side effects). Common side effects of antibiotics can include gastrointestinal symptoms (like nausea or diarrhea), headache, and skin rashes. More serious side effects are also being monitored, including effects on heart rhythm and kidney function[4].

Special Considerations for Tebipenem Use

Several factors are being studied that may affect how Tebipenem is used:

  • Kidney Function: People with reduced kidney function may need dose adjustments, as the kidneys play a role in eliminating the drug from the body[2].
  • Food Effects: Studies are looking at whether taking Tebipenem with food affects how the body absorbs the medication[3].
  • Drug Interactions: The potential for Tebipenem to interact with other medications, particularly antacids and acid-reducing drugs, is being investigated[5].
Aspect Details
Drug Name Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
Drug Class Carbapenem antibiotic
Administration Oral (tablets)
Dosage Range 300 mg to 600 mg, typically every 8 hours
Main Study Areas Tissue penetration, pharmacokinetics, safety, bioequivalence, drug interactions
Patient Groups Healthy volunteers, diabetic patients with wound infections, patients with varying degrees of renal function
Key Measurements Drug concentration in blood and tissues, QT interval changes, adverse events
Potential Applications Treatment of various bacterial infections, including complicated urinary tract infections and acute pyelonephritis

FAQ

  • What is Tebipenem Pivoxil Hydrobromide? Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) is an oral antibiotic being studied for its potential to treat various infections. It belongs to a class of antibiotics called carbapenems, which are usually given intravenously.
  • What types of infections might TBPM-PI-HBr treat? Based on the clinical trials, TBPM-PI-HBr is being studied for treating lower limb wound infections in diabetic patients and other bacterial infections. Its broad-spectrum activity suggests it could be effective against a wide range of bacteria.
  • How is TBPM-PI-HBr administered? TBPM-PI-HBr is given orally, usually in tablet form. The dosage varies in different trials, ranging from 300 mg to 600 mg, typically given every 8 hours.
  • Are there any special considerations for patients with kidney problems? Yes, one of the trials specifically studied how TBPM-PI-HBr behaves in patients with various degrees of kidney function, including those with end-stage renal disease on hemodialysis. This suggests that dosing may need to be adjusted for patients with kidney issues.
  • What are the main side effects being monitored in these trials? The trials are monitoring for a range of potential side effects, including changes in heart rhythm (QT interval), gastrointestinal issues, and any other adverse events. They're also closely watching for any significant changes in laboratory values, vital signs, and physical examination findings.

Ongoing Clinical Trials on Tebipenem Pivoxil Hydrobromide

  • Title: Comparison of oral tebipenem pivoxil versus intravenous imipenem-cilastatin in adults with complicated urinary tract infection or acute pyelonephritis

    Not recruiting

    1 1 1
    Investigated drugs:
    Bulgaria Croatia Estonia Greece Hungary Latvia +3

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • QT interval: A measurement on an electrocardiogram that represents the time it takes for the heart's electrical system to fire and then recharge. Changes in this interval can indicate potential heart rhythm problems.
  • Bioequivalence: A term used to describe when two medications are expected to have the same clinical effect and safety profile, usually applied when comparing a generic drug to a brand-name drug.
  • Microdialysis: A technique used to sample chemicals from the fluid in tissues, often used to measure drug concentrations in different parts of the body.
  • Area Under the Curve (AUC): A measurement used in pharmacology to describe the total drug exposure over time.
  • Maximum plasma concentration (Cmax): The highest concentration of a drug in the blood plasma after it has been administered.
  • Half-life: The time it takes for the concentration of a drug in the body to reduce by half.
  • Renal clearance: The volume of blood plasma that is completely cleared of a substance by the kidneys per unit time.
  • Hemodialysis: A process of purifying the blood of a person whose kidneys are not working normally.

References

  1. https://clinicaltrials.gov/study/NCT04919954
  2. https://clinicaltrials.gov/study/NCT04178577
  3. https://clinicaltrials.gov/study/NCT04421885
  4. https://clinicaltrials.gov/study/NCT04238195
  5. https://clinicaltrials.gov/study/NCT04368585